Healthcare Review: Hemispherx BioPharma, Cambrex & VIVUS Jump Print E-mail
By Staff and Wire Reports   
Tuesday, 14 August 2012 14:23
icon_SectorWatchU.S. stocks were trading slightly higher on Tuesday as a rebound in July retail sales data lifted consumer stocks and economic data out of Europe showed fractional improvement. Several healthcare stocks are making notable news at mid day on Tuesday:

VIVUS, Inc. (NASDAQ:VVUS) shares gained 3.45% to $22.47 in the morning hour. On August 7, 2012, the company reported a larger-than-expected second-quarter loss, as it spent more ahead of marketing the newly-approved product. Net loss widened to $24.0 million, or $0.24 per share, from $16.2 million, or $0.20 per share, in the same quarter a year earlier. Analysts on average had expected a loss of $0.23 per share. The company did not report revenue as it does not currently sell any drug.

STAAR Surgical Company (NASDAQ:STAA) stock gained 3.01% to $6.66. On August 9, 2012, the company announced that it will participate in the 32nd Annual Canaccord Growth Conference at the Intercontinental Hotel in Boston. STAAR's presentation will be on Wednesday, August 15, 2012 at 10:30 a.m. Eastern Time. Barry G. Caldwell, President and CEO, will review the company's recent financial results and current business developments. Deborah Andrews, CFO, will also be attending.

MannKind Corporation (NASDAQ:MNKD) stock increased 0.66% to $2.28. On August 9, 2012, Zacks reaffirmed their neutral rating on shares of MannKind and currently have a $2.25 price target on the stock. The analysts believe that the company will look to raise funds again later this year. Inability to raise sufficient funds will jeopardize Afrezza’s future. Hence they remain Neutral on the stock.

Hemispherx BioPharma, Inc (NYSEAMEX:HEB) shares climbed 9.12% to $0.480 in the early hour after the company announced that it filed on July 31, 2012 with the U.S. Food and Drug Administration complete response to the FDA's November 25, 2009 Complete Response Letter in support of Ampligen's New Drug Application for Chronic Fatigue Syndrome (CFS). On August 10, 2012, the FDA acknowledged in writing receipt of the Company's August 1, 2012, response stating, "It considers this a complete, class 2 response to November 25, 2009, action letter. Therefore, the user fee goal date is February 2, 2013.

Cambrex Corporation (NYSE:CBM) shares climbed 4.11% to $11.90 in the morning hour. The 52 week trading range for the company is $4.15 - $12.08. The shares of the company made a new 52 week high today. The shares of the company soared over 147% in the last one year. The company is a life sciences company, which provides products and services, which accelerate and improve the development and commercialization of new and generic therapeutics.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus